Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Sponsor
Qilu Hospital of Shandong University
Study ID
NCT04782089
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a Phase II, Open, Single-center Study of Camrelizumab and Fluzoparib as Consolidation Treatment for Patients With Extensive stage small cell lung cancer Who Have Not Progressed after first-line treatment

Key Dates

Start date
May 6, 2021
Status verified
Feb 2021
Primary completion
May 1, 2023
Completion
Jun 1, 2024

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab+Fluzoparib

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: Approximately 3 years ]

Central Contacts

Related Studies